Avenue Therapeutics Inc. (ATXI)
1.01
-0.09 (-8.18%)
At close: Mar 03, 2025, 3:55 PM
1.01
0.00%
After-hours: Mar 03, 2025, 03:56 PM EST
Company Description
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting.
Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain.
The company was incorporated in 2015 and is based in New York, New York.
Avenue Therapeutics Inc.
| Country | United States |
| IPO Date | Jun 27, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Dr. Alexandra MacLean M.D. |
Contact Details
Address: 1140 Avenue of the America New York, New York United States | |
| Website | https://www.avenuetx.com |
Stock Details
| Ticker Symbol | ATXI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001644963 |
| CUSIP Number | 05360L205 |
| ISIN Number | US05360L3042 |
| Employer ID | 47-4113275 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Alexandra MacLean M.D. | Chief Executive Officer & Director |
| David Jin | Interim Chief Financial Officer, Chief Operating Officer & Corporate Secretary |
| Dr. Lindsay Allan Rosenwald | Executive Director |
| Dr. Scott A. Reines M.D., Ph.D. | Interim Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Feb 14, 2025 | SCHEDULE 13G | Filing |
| Jan 03, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Jan 03, 2025 | 3 | Filing |
| Dec 04, 2024 | S-3 | Filing |
| Dec 03, 2024 | 4 | Filing |
| Nov 29, 2024 | 8-K | Current Report |
| Nov 15, 2024 | SC 13D/A | [Amend] Filing |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 14, 2024 | 8-K | Current Report |